Generative AI and the New Dawn of Life Sciences and Healthcare

Dr. John J. Sviokla is an executive fellow at Harvard Business School and cofounder of GAI Insights, a research, best practices, and executive education firm whose mission is to help organizations, communities, and individuals understand, and ethically derive value, from the power of GenAI and AI.  Before GAI Insights, John helped grow PwC’s US advisory business from $1B to $3B while also serving as chief marketing officer and head of global thought leadership. Before that he was vice chairman at Diamond Technology Partners, a pioneering digital consultancy. He is an active author, frequent speaker, and board member.

During his twelve years on the faculty of Harvard Business School, John pioneered the very first courses on AI and electronic commerce. He is the author of three books: Seeking Customers, Keeping Customers, and The Self Made Billionaire Effect.  

John earned his BA from Harvard College and his MBA and Doctorate from Harvard Business School.

Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of experience in the healthcare and tech sectors. Luba has served as the chief executive officer and chair of the board of Kojin Therapeutics, a leader in ferroptosis. She currently serves as the managing partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has founded.

Ms. Greenwood has extensive board experience globally and serves on public and private boards across multiple industries, including healthcare and tech, and has successfully contributed to the growth and profitability of numerous organizations. With a strong understanding of board dynamics and corporate governance best practices, and as a former lawyer, she has also guided organizations through compliance, activist actions, and human resources challenges. She has served as chair of the board as well as on the compensation, audit, and nomination committees of a number of companies including In8Bio (INAB), BenchSci, Swiss-based Stalicla, Abcam (Abcam), where she has spearheaded the sale to Danaher (DHR), and nonprofit Massachusetts Biotechnology Council (MassBio).
 

Ashwini Ghogare is the head of AI and Automation for Drug Discovery at MilliporeSigma, and intrapreneur of the corporate venture on AI-powered drug discovery and automation across life sciences and healthcare. Ashwini is a leader in transformational drug discovery technologies with extensive experience in software development, new business incubation, and software product sales. Ashwini has previously led strategic initiatives to identify transformative AI technologies for drug discovery applications and successfully built and launched a new AI-powered drug design solution, AIDDISON™. She was also responsible for the global services and commercial licensing of Synthia™, MilliporeSigma’s flagship retrosynthesis software product. She has a PhD in organic chemistry in photobiology, focused on the photochemical drug delivery system that led to the creation of a start-up, SingletO2 Therapeutics LLC.

Dr. Joan LaRovere is associate chief medical officer for transformation and an attending physician in Cardiovascular Critical Care at Boston Children’s Hospital.

Dr. LaRovere is cofounder and president of Virtue Foundation, an NGO with Special Consultative Status to the United Nations, where she is focused on a data-driven, evidence-based approach to development. The foundation aims to deliver quality healthcare to those in need while working to create an efficient marketplace for global healthcare delivery through machine learning and artificial intelligence. Dr. LaRovere has launched VFMatch, an innovative technology platform that intelligently matches healthcare needs with resources in 72 low- and lower-middle income countries.

Dr. LaRovere is a healthcare operating partner with iSelect Fund, a venture firm investing in healthcare and agriculture. She is also a professional advisor to the Martin Trust Center for MIT Entrepreneurship, and faculty or a mentor to several courses in entrepreneurship, healthcare finance, AI in healthcare and the science and business of biotech at the MIT Sloan School, where she received her Executive MBA in 2016.